Telix Pharmaceuticals Limited (ASX:TLX)
14.60
-0.35 (-2.34%)
Aug 29, 2025, 4:10 PM AEST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M USD in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
4.88
Revenue / Employee
$2.84M
Employees
234
Market Cap
4.94B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.85B |
Ansell | 3.06B |
Mesoblast | 26.23M |
Neuren Pharmaceuticals | 218.86M |
Telix Pharmaceuticals News
- 1 day ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman - GlobeNewsWire
- 1 day ago - Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable - Seeking Alpha
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - GlobeNewsWire
- 2 days ago - Telix Gets Second FDA Rejection For Kidney Cancer Drug - Benzinga
- 2 days ago - Telix Gets Second FDA Rejection For Kidney Cancer Drug - Benzinga
- 2 days ago - US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer - Reuters
- 3 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX - PRNewsWire
- 4 days ago - Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman - GlobeNewsWire